CORDIS
EU research results

CORDIS

English EN
CARdiomyopathy in type 2 DIAbetes mellitus

CARdiomyopathy in type 2 DIAbetes mellitus

Objective

A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbidities such as heart diseases. While ischaemic heart disease represents the major cause of death of T2DM patients, heart failure (80% of Heart Failure with preserved Ejection Fraction) is the second most common cardiovascular disease in T2DM patients. The aim of CARDIATEAM is to determine whether T2DM represents a central mechanism contributing to the pathogenesis and progression of a specific cardiomyopathy, called “diabetic cardiomyopathy” (DCM), assessing whether DCM is unique and distinct from the other forms of heart failure.
To achieve this aim CARDIATEAM will build up a deeply phenotyped cohort, including an innovative imaging protocol, based on privileged access within the CARDIATEAM to already existing highly pertinent cohorts of diabetes and heart failure patients and control groups. Central biobanking of the cohort samples will allow detailed omics analysis that will feed together with the phenotype and imaging data into the central CARDIATEAM database. The data gathered will enable unsupervised machine-learning for clustering this heterogeneous population on phenotypic differences beyond diabetes. State-of-the-art big-data processing techniques and disease modeling will allow for controlling for common confounders such as BMI, smoking, age and blood pressure and will finally lead to the identification of new imaging and molecular biomarkers as well as understanding the taxonomy of the development and progression of DCM. Tailored preclinical models will be developed to explore the identified pathways revealing new therapeutic targets.
The results of CARDIATEAM will be able to impact clinical care with the stratification of patients into risk groups of developing DCM, earlier diagnosis of DCM and an improvement of therapy thanks to better assessment of underlying pathophysiology and identification of new biomarkers.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 240 727,80

Participants (20)

Sort alphabetically

Sort by EU Contribution

Expand all

CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.

Spain

EU Contribution

€ 655 500

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 200 000

STICHTING NETHERLANDS HEART INSTITUTE

Netherlands

EU Contribution

€ 605 000

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 550 001

HOSPICES CIVILS DE LYON

France

EU Contribution

€ 202 708,70

UNIVERSITE D'AIX MARSEILLE

France

EU Contribution

€ 213 375

UNIVERSITAETSKLINIKUM AACHEN

Germany

EU Contribution

€ 138 750

UNIVERSITATSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 124 975

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 94 782,50

LUXEMBOURG INSTITUTE OF HEALTH

Luxembourg

EU Contribution

€ 588 156,25

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 407 616,25

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 269 526,25

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 30 000

SIB INSTITUT SUISSE DE BIOINFORMATIQUE

Switzerland

EU Contribution

€ 648 000

OPALE

France

EU Contribution

€ 392 481,25

METABRAIN RESEARCH

France

EU Contribution

€ 28 150

INSERM TRANSFERT SA

France

EU Contribution

€ 310 250

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

Bayer

Germany

Eli Lilly and Company Limited

United Kingdom

Project information

Grant agreement ID: 821508

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    29 February 2024

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 12 882 500

  • EU contribution

    € 6 700 000

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France